文献速递神经免疫

应用独立于复发活动的进展框架揭示多发性硬化的病理生物学基础

Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
PubMed 文献 · Neurology · 2024-06-18

本文讨论独立于复发活动的进展(PIRA)作为多发性硬化残疾累积指标的定义缺陷与实施挑战,指出PIRA依赖扩展残疾状态量表且忽略认知等维度,并提出在无定期MRI的观察性队列中用PIRA、在有常规与先进影像时用「advanced-PIRMA」研究残疾累积的病理生物学基础。

要点

  • PIRA假设急性炎症与神经变性可通过特定时间窗区分,但临床与影像评估实施困难。
  • PIRMA指无临床复发且无新发脑和脊髓MRI病灶的残疾累积,临床实践中评估极具挑战。
  • 作者提出在无定期MRI的观察性队列中用PIRA,并用advanced-PIRMA结合先进影像研究残疾累积机制。

核心结论

  • 作者提出用PIRA理解无定期MRI的观察性队列中残疾累积的主要决定因素,并引入advanced-PIRMA以常规与先进影像研究上述过程对残疾累积的贡献。
  • 作者认为MRI比纯临床描述更能反映多发性硬化致病机制,影像无法解释的残余残疾累积将提示未来研究重点。

研究设计与样本

  • 本文为论述性文章,讨论PIRA作为潜在临床试验结局指标的缺点及其在临床、实验试验和研究中的实施挑战。

主要发现

  • 当前PIRA定义假设急性炎症(可表现为复发)与神经变性(表现为进展性残疾累积)可通过引入复发起病与观察到的残疾增加之间的特定时间窗来区分。
  • PIRMA(独立于复发和MRI活动的进展)指无临床复发且无新发脑和脊髓MRI病灶时的残疾累积。
  • PIRA常用扩展残疾状态量表评估,该量表偏重运动残疾,而采用复合指标或数字工具等更精细评估残疾恶化(包括认知下降)可能更有用。
  • 与复发无关的残疾累积的病理生物学基础可能包括慢性活动性病灶(缓慢扩大病灶和顺磁性边缘病灶)、皮质病灶、脑和脊髓萎缩(尤其灰质)、弥漫性和局灶性小胶质细胞激活、持续性柔脑膜强化以及白质传导束损伤。

临床怎么用

  • 作者提出在无定期MRI的观察性队列研究中使用PIRA理解残疾累积的主要决定因素。
  • 作者提出使用advanced-PIRMA,结合常规和先进影像研究上述过程对残疾累积的贡献。
  • 作者认为在临床实践中评估PIRMA极具挑战,因为需要频繁的临床评估以及脑和脊髓MRI扫描。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progression independent of relapse activity (PIRA), a recent concept to formalize disability accrual in multiple sclerosis (MS) independent of relapses, has gained popularity as a potential clinical trial outcome. We discuss its shortcomings and appraise the challenges of implementing it in clinical settings, experimental trials, and research. The current definition of PIRA assumes that acute inflammation, which can manifest as a relapse, and neurodegeneration, manifesting as progressive disability accrual, can be disentangled by introducing specific time windows between the onset of relapses and the observed increase in disability. The term PIRMA (progression independent of relapse and MRI activity) was recently introduced to indicate disability accrual in the absence of both clinical relapses and new brain and spinal cord MRI lesions. Assessing PIRMA in clinical practice is highly challenging because it necessitates frequent clinical assessments and brain and spinal cord MRI scans. PIRA is commonly assessed using Expanded Disability Status Scale, a scale heavily weighted toward motor disability, whereas a more granular assessment of disability deterioration, including cognitive decline, using composite measures or other tools, such as digital tools, would possess greater utility. Similarly, using PIRA as an outcome measure in randomized clinical trials is also challenging and requires methodological considerations. The underpinning pathobiology of disability accumulation, that is not associated with relapses, may encompass chronic active lesions (slowly expanding lesions and paramagnetic rim lesions), cortical lesions, brain and spinal cord atrophy, particularly in the gray matter, diffuse and focal microglial activation, persistent leptomeningeal enhancement, and white matter tract damage. We propose to use PIRA to understand the main determinant of disability accrual in observational, cohort studies, where regular MRI scans are not included, and introduce the term of "advanced-PIRMA" to investigate the contributions to disability accrual of the abovementioned processes, using conventional and advanced imaging. This is supported by the knowledge that MRI reflects the MS pathogenic mechanisms better than purely clinical descriptors. Any residual disability accrual, which remains unexplained after considering all these mechanisms with imaging, will highlight future research priorities to help complete our understanding of MS pathogenesis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ciccarelli O, Barkhof F, Calabrese M, et al. Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis. Neurology. 2024. PMID: 38889384. doi:10.1212/WNL.0000000000209444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。